What Is PHMB Antimicrobial and How Does It Work?

Polyhexamethylene biguanide, commonly shortened to PHMB, is a synthetic polymer with a strong positive electrical charge that kills or inhibits bacteria, fungi, and some viruses on contact. It works primarily by latching onto the negatively charged surfaces of microbial cells, disrupting their outer membranes and, as more recent research has shown, entering the cell to damage its DNA. You will find PHMB in wound dressings, eye-infection treatments, swimming-pool sanitizers, and multipurpose contact lens solutions, among other products. Its wide use reflects a profile that is unusual among antimicrobials: broad killing power paired with relatively low toxicity to human tissue at the concentrations typically used in clinical settings.

What PHMB Actually Is

PHMB is a long-chain polymer built from repeating biguanide units connected by six-carbon (hexamethylene) linkers. Because each biguanide group carries a positive charge at physiological pH, the whole polymer behaves like a string of tiny magnets attracted to anything with a negative surface charge, including bacterial cell membranes. It is classified as a polycationic antimicrobial polymer and has been in commercial use since the 1970s, originally as a pool and spa disinfectant before migrating into healthcare.

The polymer comes in various molecular-weight distributions depending on the manufacturer and intended application. This is worth knowing because chain length influences both antimicrobial potency and tissue compatibility. A study examining how alkyl chain length governs the structure of poly(alkylene biguanide) polymers confirmed that PHMB’s broad-spectrum activity against bacteria, fungi, and viruses is tied to the specific geometry of its repeating units, which is why it is so widely used for infection prevention in medical settings.¹

How It Kills Microbes

For decades, the standard explanation was straightforward: PHMB’s positively charged biguanide groups bind electrostatically to the negatively charged phospholipid headgroups on a bacterium’s outer membrane, and this interaction physically disrupts the membrane, causing the cell contents to leak out. Molecular dynamics simulations have added nuance to this picture. The polymer adsorbs onto the membrane surface through those electrostatic attractions, then partially penetrates the lipid bilayer, disturbing its structure. Interestingly, this does not punch clean holes or form pores.² Instead, the disruption is subtler, more like warping a fence than knocking a gate open.

The bigger surprise came from research published in Scientific Reports showing that membrane disruption is only part of the story. PHMB actually enters bacterial cells across a range of species and, once inside, binds directly to chromosomal DNA, condensing it into compact clumps. Bacteria treated this way stop dividing. The researchers confirmed this DNA-level mechanism by showing that PHMB forms nanoparticles when mixed with isolated bacterial chromosomal DNA, and that its growth-inhibiting effects could be blocked by co-treating with another DNA-binding compound.³ So PHMB has a dual attack: it weakens the outer envelope and then sabotages the DNA inside. That two-pronged approach is part of why resistance to PHMB has remained uncommon compared to conventional antibiotics.

What It Works Against

PHMB’s killing range is genuinely broad. It is effective against Gram-positive bacteria such as Staphylococcus aureus and Bacillus subtilis, Gram-negative species including Escherichia coli, Pseudomonas aeruginosa, and Vibrio parahaemolyticus, various fungi, and even some viruses.⁴ Laboratory testing on marine aquaculture pathogens found minimum inhibitory concentrations ranging from about 4 to 125 micrograms per milliliter depending on the species, with a stronger bactericidal effect against Gram-negative marine bacteria than against common lab strains of E. coli and S. aureus.⁵

On the viral side, evidence is more limited but intriguing. PHMB demonstrated modest activity in the laboratory against HIV-1, interfering with the virus’s ability to bind to and enter host cells.⁶ “Modest” is the key word here; nobody is proposing PHMB as an antiviral drug, but the finding suggests its membrane-targeting mechanism extends to enveloped viruses, which share certain structural features with bacterial membranes.

Tackling Biofilms

One of the toughest problems in infection control is the biofilm, a slimy, matrix-enclosed community of bacteria that is dramatically harder to kill than free-floating cells. Most antiseptics struggle against mature biofilms. PHMB does better than many alternatives in this regard, though it has clear limits.

At concentrations as low as 0.02%, about ten times lower than what is found in many commercial wound-cleansing products, PHMB strongly inhibited growth, initial surface attachment, and biofilm formation across multiple pathogen species. It also disrupted biofilms that were already established.⁷ However, head-to-head comparisons with povidone-iodine (the familiar brown surgical antiseptic) paint a more mixed picture. Povidone-iodine acted faster against MRSA biofilms and completely eradicated Pseudomonas biofilms of various ages, while PHMB only partially reduced Pseudomonas biofilm density even after 24 hours of exposure.⁸ So PHMB is a capable anti-biofilm agent, but not always the strongest one available.

Formulation helps close the gap. When PHMB is combined with EDTA (a chelating agent that weakens the outer membrane of Gram-negative bacteria) and a surfactant, the mixture reduced biofilm viability by more than five logarithmic units, far exceeding what any single component achieved alone. Against MRSA biofilm, the combination achieved complete elimination with no regrowth in recovery cultures.⁹ EDTA works by stripping away the divalent metal ions that hold the Gram-negative outer membrane together, essentially opening a door for PHMB to walk through.¹⁰

Wound Care Applications

Wound care is where PHMB has found some of its most established clinical use. PHMB-impregnated foam dressings, gauze, and irrigation solutions are commercially available and widely used for chronic wounds such as diabetic ulcers, venous leg ulcers, and pressure injuries. A clinical trial comparing PHMB foam dressings against plain foam found that the PHMB group had significantly lower bacterial burden at four weeks, with polymicrobial organisms recovered in only about 5% of PHMB-treated wounds versus a third of controls. Pain scores also dropped meaningfully by week two. Wound size shrank by a median of 35% in the PHMB group compared with 28% in the control group.¹¹

For chronic wounds treated with a collagen matrix combined with PHMB, about three-quarters showed measurable wound-area reduction at 12 weeks, and roughly a third achieved full closure, with an average time to closure of under seven weeks.¹² In more challenging scenarios, like biofilm-colonized cancer wounds, PHMB-betaine dressings combined with silver sulfadiazine cleared necrotic tissue and eliminated detectable microorganisms within two weeks, preparing the wound bed for surgical reconstruction.¹³

How PHMB Compares to Other Antiseptics

Clinicians choose among several antiseptics depending on the situation, and PHMB occupies a particular niche. Compared with povidone-iodine, PHMB tends to cause less pain and tissue irritation. In a trial of preoperative eye antisepsis for cataract surgery, patients in the povidone-iodine group reported significantly more pain, with 17 patients experiencing severe or excruciating pain, while no patients in the PHMB or chlorhexidine groups reported pain at those levels.¹⁴

In vitro testing of all three disinfectants against wound-relevant bacteria found that PHMB had better antibacterial efficacy against S. aureus, and all three tested bacterial species were more sensitive to PHMB than to the other disinfectants. All three were cytotoxic to human skin cells in direct contact, but povidone-iodine was the most cytotoxic even at low concentrations.¹⁵ That said, PHMB is not always the gentlest option. One comparison found that PHMB showed high toxicity to cultured cell lines even at low concentrations, while a related polymer called polyaminopropyl biguanide (PAPB) was less toxic while retaining antimicrobial activity.¹⁶ The practical takeaway is that PHMB’s tissue-friendliness is real but not absolute; concentration and formulation matter enormously.

Treating Acanthamoeba Eye Infections

One of PHMB’s most important medical roles is in treating Acanthamoeba keratitis, a rare but sight-threatening parasitic infection of the cornea most commonly associated with contact lens wear. Acanthamoeba is notoriously hard to kill because it forms cysts that are resistant to many drugs. PHMB has become a first-line treatment for this infection.

A landmark trial known as the ODAK trial compared high-dose PHMB (0.08%) used alone against the conventional dual-drug regimen of lower-dose PHMB (0.02%) plus propamidine. The high-dose PHMB monotherapy met the predefined threshold for noninferiority, with adjusted cure rates of about 87% in both groups, median final visual acuity of 20/20 in both groups, and no serious drug-related adverse events in either arm.¹⁷ Being able to use a single drug instead of two simplifies treatment and could reduce costs.

Indirect comparisons with historical treatment data are even more striking. PHMB 0.08% achieved a complete resolution rate of about 85%, compared with roughly 55% for the conventional PHMB-plus-diamidine combination and about 40% for corneal cross-linking regimens used at other centers.¹⁸ A smaller case series of high-dose PHMB monotherapy showed complete corneal healing in 11 of 12 treated eyes, with no relapses after three months off treatment.¹⁹ For a condition that has historically carried a real risk of corneal transplant or permanent vision loss, these results are encouraging.

Swimming Pools, Contact Lenses, and Other Consumer Uses

Outside of hospitals, you are most likely to encounter PHMB in swimming pool and spa water. It has been marketed as a chlorine-free alternative for pool sanitation since the 1980s. In a laboratory pool model, PHMB at 10 mg/L achieved at least a four-log reduction in biofilm density, though biofilm could still accumulate over time, and periodic shock treatments were the most effective way to keep it in check.²⁰ Pool owners who use PHMB-based systems often appreciate the absence of the harsh smell and skin irritation associated with chlorine, though maintaining proper PHMB levels requires testing, historically done via colorimetric methods.²¹

PHMB is also a common preservative in multipurpose contact lens solutions, where it works at very low concentrations (around 0.0001%) to prevent microbial contamination in the bottle and on the lens. Analytical methods can detect levels as low as 0.1 parts per million in these solutions.²² Some contact lens wearers experience sensitivity to PHMB-preserved solutions, which can manifest as eye redness or discomfort. If that happens, switching to a hydrogen-peroxide-based system usually resolves the issue.

Can Bacteria Become Resistant to PHMB?

The dual mechanism described earlier, attacking both the membrane and the DNA, makes it harder for bacteria to evolve resistance to PHMB than to a conventional antibiotic targeting a single molecular pathway. Harder, but not impossible. Research on E. coli biofilms exposed to PHMB found that the biocide promoted the emergence of bacteria with increased tolerance to gentamicin, an unrelated antibiotic. These cross-resistant variants tended to carry mutations in genes involved in cellular respiration and showed increased expression of genes related to biofilm matrix production and stress responses.²³

The reassuring part is that most of these resistant variants lost their gentamicin tolerance once PHMB exposure stopped, indicating a transient adaptive response rather than permanent genetic resistance. Only a small fraction retained stable resistance. Still, this finding is a reminder that biocides are not immune to the broader problem of antimicrobial resistance, especially in biofilm settings where bacteria are already in a stress-tolerant state.

Safety Limits and Regulatory Caution

PHMB’s safety profile is generally favorable at the concentrations used in wound care and disinfection, but regulators have drawn some firm lines. The European Union’s Scientific Committee on Consumer Safety concluded that PHMB is not safe for use in cosmetic spray products and is not safe in all cosmetics up to the maximum concentration of 0.3%. The committee recommended that safe use would require a lower concentration or restrictions on which product types can contain it.²⁴ The concern centers on inhalation risk with spray formulations and on skin sensitization at higher concentrations.

Contact allergy to PHMB does occur, but it remains uncommon. A large patch-testing study of nearly 2,000 consecutive patients found positive reactions in only about 0.5% at the test concentration. The researchers noted that some of these may have been false positives, and the reaction pattern suggested occupational exposure (cleaning products, medical settings) as the most probable cause of sensitization rather than consumer cosmetic use.²⁵ Animal studies indicate that PHMB becomes a moderate to strong sensitizer above about 1.2%, which is why the threshold for concern was set around that range.²⁶

Environmental Persistence and Aquatic Toxicity

PHMB is highly toxic to some aquatic organisms, which raises environmental questions given how much of it goes down drains from pools, hospitals, and personal care products. Testing found that about 80% of PHMB persisted in fortified creek water samples after 20 days, indicating slow breakdown in open water. However, it bound almost immediately to most soil types, with the exception of sandy soil.²⁷ That rapid soil binding means PHMB is unlikely to travel far through groundwater, but the aquatic toxicity and water-phase persistence are genuine concerns for waterways that receive direct discharge.

Veterinary Uses

PHMB-impregnated gauze has been tested in veterinary medicine for wound management in dogs and horses. In dogs, PHMB dressings did not heal wounds faster than standard gauze with saline cleaning, but they also did not impair healing, positioning them as a viable option when antimicrobial wound coverage is desired.²⁸ In horses, a 0.2% PHMB gauze inhibited the growth of Staphylococcus species by up to about 83% and E. coli by up to 37%, but it showed no inhibition against Pseudomonas aeruginosa or Enterococcus species.²⁹ That gap against Pseudomonas is consistent with the pattern seen in human wound-care research: Pseudomonas biofilms are among the hardest targets for PHMB alone, which is why combination strategies involving EDTA or other agents become important in both human and animal wound management.

PHMB-impregnated gauze has also been tested against common veterinary pathogens on inoculated plates, where it provided greater inhibition of all four Gram-positive species tested and two of six Gram-negative species compared with control gauze. No bacteria survived on PHMB-impregnated gauze placed in sterile wells.³⁰ Taken together, the veterinary data suggest PHMB is a reasonable wound-care tool for animals but, just as in human medicine, works best as part of a broader management strategy rather than as a standalone solution.